Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | POLG | P54098 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895002 | 0.84 | POLB (0.61) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL1971070 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL18784963 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL12595477 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL12940502 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL23751346 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL17833253 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL48317 | 0.81 | POLB (0.80) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL29099745 | 0.80 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL1886858 | 0.80 | POLB (0.65) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242087-B2 | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-08-14 | — | — | US | disclosed |
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-04-15 | — | — | US | disclosed |
| EP-2144921-A2 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. Leuven Research and Development (BE) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008104408-A2 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | POLB 12/4885P2RY2 1009/4885P2RY4 628/4885 |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | POLB 12/4885P2RY2 1009/4885P2RY4 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.